The most highly cited article in the local dataset was PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. This evidence concerns the gene ESR1 and breast carcinoma.